,22 In this context, immunotherapy has emerged as a promising treatment option, as evidenced by the recent approval of programmed cell Death Protein 1 (PD-1) blocking antibodies for the treatment of recurrent or metastatic cervical cancer. The gene discussed is PDCD1; the disease is cervical carcinoma.